

Beat: Politics

PDT MACRON DESIRES HEALTH SOVEREIGNTY BY PRODUCING 250M VACCINE DOSES IN FRANCE

VISIT OF DELPHARM IN EURE ET LOIRE

Paris, Washington DC, 12.04.2021, 19:11 Time

USPA NEWS - The President of the French Republic Emmanuel Macron visited, on Friday April 9, on the site of the company Delpharm in Eure-et-Loir, on Friday April 9, 2021, in the presence of Mr. Matthieu Landon, technical advisor industry, research and innovation and Lucile Poivert, health advisor, consumer goods, Europe in the office of Agnes Pannier-Runacher.

The President's visit follows his recent announcement of France's desire to release 250 million doses of vaccines by the end of this summer. "[?]The Delpharm laboratory will therefore achieve 15% inhibitor production in France from PfizerBioNtech vaccine.

PRESIDENT MACRON'S DESIRE IS TO MARK FRENCH HEALTH SOVEREIGNTY BY PRODUCING THE VACCINES IN FRANCE-----

President Macron, who made a three hours (3h) visit on Friday April 9 to the Delpharm site, was welcomed by Françoise Souliman, prefect of Eure-et-Loire, elected officials of the department and Francois Bonneau, the president of the Region Center-Val de Loire. The President of the Republic was guided in this visit by Sebastien Aguetant, General Director and Vladimir Guital, director of the Delpharm site in Saint-Remy-sur-Avre. President Emmanuel Macron's visit began with greetings and encouragement, even congratulations to the employees of the vaccine visual inspection workshop, then the labeling workshop before going to the fifty or so super-freezers to listen to the scientific and technical explanations of the preservation of the Pfizer-BioNTech vaccine. The welcome was warm and vis a vis the President of the Republic who even agreed to pose for a photo with some of the lab's staff.

THE FRENCH HEAD OF STATE MACRON PRAISES THE POLEPHARMA SITE OVER A "FRENCH PRIDE", LEADING TO INDUSTRIAL ATTRACTIVNESS-----

President Macron recalled the importance of industrial attractiveness in France, based on the policy he is leading for relocation to France and in particular the pharmaceutical sector, including the example of the Polepharma site, in Eure et Loir: "I greet the elected representatives of the territory and the Region, whom I met this morning. Polepharma is the heart of the industrial identity of this territory and this region. And it is a French pride. This is why I want us to continue in line with what we launched three years ago now, with work on the return of a policy of industrial attractiveness, even before we know this crisis. Our objective is to redevelop our pharmaceutical industry, to give visibility on the price of the drug and to allow, at the same time, pharmaceutical innovation, but also the maintenance of production sites with long-term visibility, as well as manufacturing mature products. "

DELPHARM SITE TO PRODUCE OF PFIZER BIONTCEH VACCINE IN FRANCE-----

Matthieu Landon, industry, research and innovation technical advisor to the President of the French Republic , explains to the press, that the Delpharm laboratory, which President Macron is visiting, is about to produce Pfizer BioNtech vaccine vials: " At Delpharm, a considerable effort, has been made, in 24 hours, they hired 60 people, and get mobilized. This is part of the entire trajectory, to increase the production capacity of vaccines in France, for France and the European Union. -----

In June, the French President had come to call for production and health, and mentioned the launch of production which forecasts a total of 250 Million in France. » He specifies that: "15% of Delpharm's production will go to France and the rest to the European Union, and I don't know which% will be reconditioned. for production, 15% of Delpharm's production will go to France and the rest to EU, and I don't know which% will repackage. For production, it will be 100 million vaccines "[?] As for the Janssen vaccine from Johnson & Johnson, it would be produced this summer by Sanofi, another large French pharmaceutical laboratory ...These are investments made early in 2020, to materialize through this project. " he concluded, Vladimir Guital, director of the Delpharm Vladimir Guital only added: "Tens of millions of doses will be produced on our site. "./

PDT MACRON HAS NOT REVEALED THE NUMBER OF DOSES PRODUCED IN FRANCE AS IT IS UNDER CONFIDENTIALITY-----

This attempt to "re-localize"[?] the local pharmaceutical industry, including upstream and downstream partners, is reassuring on the part of President Macron Delpharm: "We have a site which has more than 240 employees and has hired 60 people. for the Pfizer-

BioNTech vaccine project. He has partners here in the region, and beyond, that he continues to put to work. In a way, Delpharm is pulling them towards this productive momentum. This is not only good for the companies that currently produce and are directly involved in the program, but it is also good for the other four sites that will participate in producing the 250 million vaccines in 2021, as well as their subcontractors and local partners. "Explained the French head of state, Emmanuel Macron. Source : Elysee, Echo Republicain

Article online:

<https://www.uspa24.com/bericht-18521/pdt-macron-desires-health-sovereignty-by-producing-250m-vaccine-doses-in-france.html>

Editorial office and responsibility:

V.i.S.d.P. & Sect. 6 MDSStV (German Interstate Media Services Agreement): Rahma Sophia Rachdi & Jedi Foster

Exemption from liability:

The publisher shall assume no liability for the accuracy or completeness of the published report and is merely providing space for the submission of and access to third-party content. Liability for the content of a report lies solely with the author of such report. Rahma Sophia Rachdi & Jedi Foster

Editorial program service of General News Agency:

United Press Association, Inc.
3651 Lindell Road, Suite D168
Las Vegas, NV 89103, USA
(702) 943.0321 Local
(702) 943.0233 Facsimile
info@unitedpressassociation.org
info@gna24.com
www.gna24.com